Search & Analyze

Sun Pharmaceutical Industries Ltd.

HealthcarePharmaceuticals & Drugs

www.sunpharma.com BSE: 524715NSE: SUNPHARMA

₹1,742.00BSE1.50%

23 Oct, 11:42 AM

₹1,742.00

₹4.21L Cr

34.79

4.87

14.85%

₹1,768.55

₹1,740.00

₹2,047.55

₹1,583.60

Customise metrics bar

Price Performance

Peer Comparison

Name
Sun Pharmaceutical Industries Ltd. SUNPHARMA	1,742.00	34.79	4,20,831.36	0.91	2,901.23	26.53%	15,299.88	10.46%	19.11
DIVI'S LAB. DIVISLAB	8,887.60	82.76	2,35,937.86	0.33	902.00	65.50%	3,080.00	27.80%	21.51
TORRENT PHAR TORNTPHARM	4,512.00	80.40	1,71,621.98	0.82	566.00	3.28%	4,921.00	54.85%	19.27
ZYDUSLIFE ZYDUSLIFE	1,127.50	25.09	1,12,468.56	0.09	990.20	-34.90%	8,017.00	21.96%	21.39
CIPLA LTD. CIPLA	1,320.20	31.87	1,06,655.08	0.98	785.55	-39.18%	7,119.28	2.33%	16.00
LAURUSLABS LAURUSLABS	1,947.15	98.74	1,05,206.89	0.10	362.07	123.94%	2,026.31	29.10%	18.20
DR.REDDY'S DRREDDY	1,228.65	32.10	1,02,552.99	0.65	435.60	-69.10%	8,099.80	-5.51%	13.75
MANKIND MANKIND	2,252.95	46.04	93,056.99	0.04	574.09	29.12%	4,030.59	12.89%	13.24

Quarterly Results

consolidated figures in ₹ Crores · Quarterly

Particulars	Mar 2024	Jun 2024	Sep 2024	Dec 2024	Mar 2025	Jun 2025	Sep 2025	Dec 2025	Mar 2026	Jun 2026
	11,982.90	12,652.75	13,291.39	13,675.46	12,958.84	13,851.40	14,478.31	15,520.54	14,611.79	15,299.88
Expenses	8,947.75	9,045.13	9,480.52	9,666.44	9,242.75	9,549.74	10,381.73	10,725.97	10,657.59	10,882.21
	3,035.15	3,607.62	3,810.87	4,009.02	3,716.09	4,301.66	4,096.58	4,794.57	3,954.20	4,417.67
	25.33%	28.51%	28.67%	29.32%	28.68%	31.06%	28.29%	30.89%	27.06%	28.87%
	504.30	532.55	482.09	149.45	251.19	-353.54	900.39	243.28	458.50	519.53
Interest	73.57	61.54	69.17	51.51	49.14	74.80	99.86	78.36	85.89	99.67
	650.36	655.13	625.91	630.56	663.79	700.55	729.50	732.33	775.47	738.72
	2,807.67	3,412.76	3,604.54	3,471.84	3,247.64	3,163.02	4,155.47	4,207.24	3,537.28	4,089.24
	5.30%	16.18%	15.74%	16.10%	33.68%	27.51%	24.80%	19.63%	23.40%	29.05%
	2,654.58	2,835.62	3,040.16	2,903.38	2,149.88	2,278.63	3,117.95	3,368.81	2,714.03	2,894.79
	11.06	11.82	12.67	12.10	8.96	9.50	13.00	14.04	11.31	12.07

Profit & Loss

consolidated figures in ₹ Crores · Annual

Particulars	FY 2021-22 (Mar)	FY 2022-23 (Mar)	FY 2023-24 (Mar)	FY 2024-25 (Mar)	FY 2025-26 (Mar)
No of Months	12.00	12.00	12.00	12.00	12.00
INCOME :
	67,191.41	43,885.68	48,496.85	52,578.44	58,462.04
	38,654.49	43,885.68	48,496.85	52,578.44	58,462.04
EXPENDITURE :
Increase/Decrease in Stock	-107.61	-686.91	292.13	150.31	343.13
Raw Material Consumed	10,459.15	11,349.07	10,370.48	10,597.05	11,200.55
Power & Fuel Cost	702.78	830.05	760.78	750.40	813.66
Employee Cost	7,300.83	8,296.03	9,429.06	9,973.12	11,418.86
Other Manufacturing Expenses	1,880.71	1,936.77	2,186.62	2,261.24	2,564.42
General and Administration Expenses	3,270.55	4,256.12	5,252.93	5,646.06	6,082.90
Selling and Distribution Expenses	4,096.33	5,226.24	5,780.26	6,576.86	7,748.24
Miscellaneous Expenses	1,169.94	1,090.75	1,675.51	1,537.24	1,799.06
	28,772.68	32,298.12	35,747.77	37,492.28	41,970.82
Operating Profit (Excl OI)	9,881.81	11,587.56	12,749.08	15,086.16	16,491.22
	1,437.42	693.75	1,628.24	2,150.57	3,211.90
	11,319.23	12,281.31	14,377.32	17,236.73	19,703.12
Interest	127.35	172.00	238.47	231.36	338.91
PBDT	11,191.88	12,109.31	14,138.85	17,005.37	19,364.21
	2,143.74	2,529.43	2,556.64	2,575.39	2,937.85
Profit Before Taxation & Exceptional Items	9,048.14	9,579.88	11,582.21	14,429.98	16,426.36
Exceptional Income / Expenses	-4,566.82	-171.45	-494.32	-677.85	-1,307.48
	4,481.32	9,408.43	11,087.89	13,752.13	15,118.88
Provision for Tax	1,075.50	847.59	1,439.45	2,772.03	3,554.36
	3,405.82	8,560.84	9,648.44	10,980.10	11,564.52
Extra items				0.00	0.00
Minority Interest	-116.55	-39.36	-33.65	-35.71	-29.23
Share of Associate	-16.54	-47.90	-38.41	-15.35	-55.87
Consolidated Net Profit	3,272.73	8,473.58	9,576.38	10,929.04	11,479.42
Profit Balance B/F	36,598.09	37,645.65	43,610.25	50,154.55	57,861.84
Appropriations	39,870.82	46,119.23	53,186.63	61,083.59	69,341.26
Equity Dividend %	1,000.00%	1,150.00%	1,350.00%	1,600.00%	1,600.00%
	13.64	35.32	39.91	45.55	47.84
Adjusted EPS	13.64	35.32	39.91	45.55	47.84

Balance Sheet

consolidated figures in ₹ Crores

Particulars	FY 2021-22 (Mar)	FY 2022-23 (Mar)	FY 2023-24 (Mar)	FY 2024-25 (Mar)	FY 2025-26 (Mar)
	239.93	239.93	239.93	239.93	239.93
Total Reserves	47,771.29	55,755.45	63,426.82	71,978.09	83,330.16
Reserve excluding Revaluation Reserve	47,771.29	55,755.45	63,426.82	71,978.09	83,330.16
	48,011.22	55,995.38	63,666.75	72,218.02	83,570.09
Minority Interest	3,054.89	3,320.09	3,459.19	267.93	309.65
Unsecured Loans	229.92		1.33	2.52	31.26
Deferred Tax Assets / Liabilities	-2,817.72	-3,487.23	-3,931.79	-4,215.11	-3,668.44
Other Long Term Liabilities	902.36	1,146.52	802.23	751.66	1,349.09
Long Term Provisions	369.07	342.91	413.89	473.80	525.07
Total Non-Current Liabilities	-1,316.37	-1,997.80	-2,714.34	-2,987.13	-1,763.02
Trade Payables	4,489.76	5,681.52	5,653.30	6,184.34	7,333.80
Other Current Liabilities	2,926.73	2,603.51	2,716.85	3,254.45	3,943.79
Short Term Borrowings	468.52	5,958.26	2,844.36	1,867.11	4,050.35
Short Term Provisions	9,323.44	5,663.09	5,769.26	6,888.31	7,294.10
Total Current Liabilities	17,208.45	19,906.38	16,983.77	18,194.21	22,622.04
Total Liabilities	66,958.19	77,224.67	81,396.00	87,693.03	1,04,738.76
Gross Block	38,707.36	43,099.95	44,320.48	45,949.61	60,321.41
Less: Accumulated Depreciation	16,042.20	19,034.51	21,072.33	23,363.33	27,499.14
Net Block	22,665.16	24,065.44	23,248.15	22,586.28	32,822.27
Capital Work in Progress	797.51	963.35	1,107.73	1,234.34	1,380.65
Non Current Investments	5,214.65	5,451.73	6,441.23	4,697.70	3,789.07
Long Term Investment	5,214.65	5,451.73	6,441.23	4,697.70	3,789.07
Long Term Loans & Advances	2,880.86	2,757.87	2,784.59	1,016.49	1,132.77
Other Non Current Assets	46.12	93.13	93.17	124.13	51.73
Total Non-Current Assets	32,093.59	37,341.33	37,921.02	35,068.56	40,847.57
Currents Investments	7,633.94	9,372.61	8,584.54	13,656.10	20,933.45
Inventories	8,925.13	10,513.05	9,868.29	10,243.33	11,492.93
Sundry Debtors	10,484.59	11,438.51	11,249.37	13,046.11	15,509.67
Cash and Bank	5,033.35	5,770.29	10,520.68	11,331.62	11,603.08
Other Current Assets	775.01	745.91	755.99	624.54	715.15
Short Term Loans and Advances	2,012.58	2,021.57	2,454.24	3,692.36	3,606.01
Total Current Assets	34,864.60	39,861.94	43,433.11	52,594.06	63,860.29
Net Current Assets (Including Current Investments)	17,656.15	19,955.56	26,449.34	34,399.85	41,238.25
Total Assets	66,958.19	77,224.67	81,396.00	87,693.03	1,04,738.76
Contingent Liabilities	3,647.11	4,061.31	4,567.19	4,276.02	1,587.05
Total Debt	930.69	6,197.88	2,845.69	1,869.63	4,081.61
	200.11	233.38	265.36	301.00	348.31
Adjusted Book Value	200.11	233.38	265.36	301.00	348.31

Cash Flow

consolidated figures in ₹ Crores

Particulars	FY 2021-22 (Mar)	FY 2022-23 (Mar)	FY 2023-24 (Mar)	FY 2024-25 (Mar)	FY 2025-26 (Mar)
No of Months	12.00	12.00	12.00	12.00	12.00
	4,481.32	9,408.43	11,087.89	13,752.13	15,118.88
Adjustment	1,974.95	2,722.56	1,554.40	1,120.36	882.03
Changes In working Capital	1,559.05	-5,661.82	1,062.13	-323.56	-1,267.79
Cash Flow after changes in Working Capital	8,015.32	6,469.17	13,704.42	14,548.93	14,733.12
Cash Flow from Operating Activities	8,984.54	4,959.33	12,134.98	14,072.09	12,419.18
Cash Flow from Investing Activities	-5,724.74	-7,943.68	-690.20	-5,306.16	-11,344.05
Cash Flow from Financing Activitie	-5,193.46	2,376.07	-6,710.16	-7,905.82	-2,512.55
Net Cash Inflow / Outflow	-1,933.66	-608.28	4,734.62	860.11	-1,437.42
Opening Cash & Cash Equivalents	6,273.03	4,508.25	4,623.73	9,285.65	10,268.77
Cash & Cash Equivalent of Subsidiaries under liquidations	41.45	566.69	1.29	-0.03	162.73
Effect of Foreign Exchange Fluctuations	127.43	157.07	-73.99	123.04	776.43
Closing Cash & Cash Equivalent	4,508.25	4,623.73	9,285.65	10,268.77	9,770.51

Ratios

Valuation

34.79

4.87

20.58

7.06

50.41

360.44

Profitability

14.85

19.11

12.02

28.21

19.78

Leverage & Liquidity

0.05

2.82

45.61

Returns

0.91

0.61

Shareholding Pattern

Numbers in percentages

Particulars	Jun '24	Sep '24	Dec '24	Mar '25	Jun '25	Sep '25	Dec '25	Mar '26	Jun '26	Sep '26
	54.48	54.48	54.48	54.48	54.48	54.48	54.48	54.48	54.48	52.68
	36.51	36.62	36.59	36.66	36.75	36.78	36.93	37.04	36.70	36.63
	9.02	8.90	8.93	8.87	8.77	8.73	8.58	8.48	8.82	10.70
	45.52	45.52	45.52	45.52	45.52	45.52	45.52	45.52	45.52	47.32
No. of Shareholders	6,73,217	6,57,317	6,89,623	7,04,983	7,23,770	7,43,877	7,10,900	6,90,957	7,10,246	7,14,266

Mutual Funds Invested(530)

Based on each fund's latest monthly portfolio · Sep 2026

A total of 346 active funds hold 9.39% in Sun Pharmaceutical Industries Ltd., contributing to ₹40.92K Cr of holdings

Fund				As of
SB SBI Nifty 50 ETFIndex	3,730.84	1.84	2,05,37,460	Sep '26
SB SBI BSE Sensex ETFIndex	2,640.45	2.28	1,45,07,940	Sep '26
IP ICICI Prudential Value Fund - Growth - Direct PlanEquity - Value Fund	2,501.44	4.37	1,37,69,894	Sep '26
IP ICICI Prudential Aggressive Hybrid Fund - Growth - Direct PlanHybrid - Aggressive Hybrid Fund	1,789.90	3.53	98,53,039	Sep '26
HD HDFC Balanced Advantage Fund - Growth - Direct PlanHybrid - Balanced Advantage	1,588.86	1.55	87,46,339	Sep '26
IP ICICI Prudential Large Cap Fund - Growth - Direct PlanLarge Cap Fund	1,587.62	2.08	87,39,509	Sep '26
SB SBI Aggressive Hybrid Fund - Growth - Direct PlanHybrid - Aggressive Hybrid Fund	1,435.11	1.67	79,00,000	Sep '26
UT UTI Nifty 50 ETFIndex	1,279.48	1.84	70,43,274	Sep '26
UT UTI BSE Sensex ETFIndex	1,244.19	2.28	68,36,189	Sep '26
NI Nippon India ETF Nifty 50 BeESIndex	1,197.71	1.84	65,93,147	Sep '26

Corporate Actions

Showing: All

Date	Type	Details
2026-10-14	Board Meeting	Quarterly Results
2026-10-07	Board Meeting	inter alia, to consider and approve the issuance of listed, rated, unsecured, redeemable non-convertible debentures ( NCDs ), in one or more tranches, on a private placement basis, for an aggregate amount not exceeding INR 15,000 Crore (Indian Rupees Fifteen Thousand Crore only), and to consider matters incidental and connected thereto.
2026-07-10	Board Meeting	Quarterly Results

Insider Trading

Date	Person	Category	Transaction Type	Shares	Value (₹)

No insider trading data available.

Sector Overview

HealthcarePharmaceuticals & Drugs

Sun Pharmaceutical Industries Ltd. operates in the Healthcare sector under the Pharmaceuticals & Drugs industry. This sector is one of the key drivers of the Indian economy and is closely tracked by the relevant Nifty sectoral index.

Company Profile

Corporate information and contact details

Key Management

12 members across the board and senior leadership

Anoop Deshpande

Company Secretary & Compliance Officer

—

Dilip Shantilal Shanghvi

Chairman

₹7.05 Cr

Mar '26

Dilip S Shanghvi

Chairman & Managing Director

₹6.48 Cr

Mar '25

Kirti Ganorkar

Managing Director

₹5.87 Cr

Mar '26

Rolf Hoffmann

Non Executive Independent Director

₹66.00 L

Mar '26

Aalok Shanghvi

Whole Time Director & Chief Operating Officer

₹9.33 Cr

Mar '26

Gautam Doshi

Non Executive Independent Director

₹98.00 L

Mar '25

Pawan Goenka

Lead Independent Director

₹1.09 Cr

Mar '26

Rama Bijapurkar

Non Executive Independent Director

₹68.00 L

Mar '25

Satyavati Berera

Non Executive Independent Director

—

Vidhi Shanghvi

Whole Time Director & Head - CHC

₹2.00 Cr

Mar '26

Andreas Eugen Busch

Non Executive Independent Director

—

SUNPHARMA Latest News

News

10 of 10 articles

EQUITY13 Oct 2026 · 14:50

Sun Pharma inches up on getting nod to raise up to Rs 10,000 crore via NCDs

The Board of Directors of the Company at its meeting held on October 12, 2026, has, inter alia, considered and approved the same

COMPANY13 Oct 2026 · 14:21

Sun Pharma gets nod to raise up to Rs 10,000 crore via NCDs

The Board of Directors of the Company at its meeting held on October 12, 2026, has, inter alia, considered and approved the same

COMPANY8 Oct 2026 · 11:41

Sun Pharma planning to raise Rs 15,000 crore via NCDs

A meeting of the Board of Directors of the Company is scheduled to be held on October 12, 2026, inter alia, to consider and approve the same

COMPANY28 Sept 2026 · 11:29

Sun Pharma inks pact with LIB Therapeutics for ‘lerodalcibep’

Sun Pharma has been granted rights to commercialize and manufacture lerodalcibep worldwide, excluding the United States and China

EQUITY28 Sept 2026 · 09:22

Sun Pharmaceutical Industries informs about press release

COMPANY9 Sept 2026 · 18:21

Sun Pharmaceutical incorporates subsidiary in GIFT City

The new entity has been incorporated to operate as the Global Treasury Centre for the Sun Pharma Group

EQUITY9 Sept 2026 · 16:40

Sun Pharmaceutical Industries informs about incorporation of subsidiary company

EQUITY1 Sept 2026 · 09:40

Sun Pharmaceutical Industries informs about press release

EQUITY17 Aug 2026 · 09:35

Sun Pharmaceutical Industries informs about update

COMPANY31 Jul 2026 · 18:02

Sun Pharma reports 27% rise in Q1 consolidated net profit

Consolidated total income of the company increased by 11.93% to Rs 16,023.50 crore for Q1FY27

SUNPHARMA

₹1,742.00

-1.5%